Oncology

With rich experience in in vivo tumor research and new drug evaluation, CIR Biopharma team has developed a large number of subcutaneous, in situ and metastatic tumor models using commercial available tumor cell lines. It has been reported in the literature that tumor cells transplanted into mice subcutaneously or into the organ of tumor origin, grow and develop in different tumor microenvironments, and their tumor molecular features and clinical phenotypes and even their sensitivity to drugs can be very different. Based on this, mouse tumor in situ and metastasis models are widely used in translational research and new drug screening. Our team has constructed a series of modified tumor cell lines using a variety of fluorescent labeling methods, which can be used in the development of in situ and metastatic tumor models. We have established strict SOPs to improve surgical throughput, multimodal non-invasive image tracking, and reduce individual differences in animals, while CIR Biopharma team has always been oriented to the needs of the clinical research (market), and has constructed a series of mouse subcutaneous and in situ PDX models by using tumor samples from patients in clinical practice, in order to carry out drug efficacy evaluation services for clients' projects.

Cancer cell-derived xenograft model (CDX) in mouse

According to the request of our customer (markets), CIR Biopharma can provide various subcutaneous xenograft tumor models constructed from human-derived tumor cell lines in immunodeficient mice for evaluating the effectiveness of drugs. The tumor types cover: lung cancer, breast cancer, gastric cancer, liver cancer, pancreatic cancer, cervical cancer, ovarian cancer and so on. At the same time, the team has completed testing of standard treatment regimens in the relevant models to evaluate the response to positive control drugs. CIR Biopharma can help clients choose targeted models for their different needs. We are committed to providing timely and efficient pharmacodynamic evaluation services with high standards and quality.

Patient-derived xenograft model (PDX) in mouse

The PDX tumor model, in which surgically removed tumor samples or tumor biopsies are directly implanted into immunocompromised or highly immunodeficient mice, offers significant advantages over traditional cell line xenograft models.

Murine syngeneic tumor model

The syngeneic model involves inoculation of a tumor cell line of homologous background origin into an immunocompetent inbred mouse. The recipient mice have an intact murine immune system that is fully immunologically active, and this immune system is compatible with the syngeneic transplanted tumor tissue, maximally mimicking the tumor microenvironment. The downside is that the transplanted mouse tissue may not fully represent the complexity of human tumors in the clinical setting. CIR Biopharma has developed a series of mouse homologous tumor models to meet the needs of our clients for new drug discovery and development. Currently, CIR Biopharma team has developed models in various tumor types such as colorectal cancer, liver cancer, pancreatic cancer, lung cancer, bladder cancer, melanoma, and lymphoma et al.

Orthotopic and metastatic tumor model

With rich experience in surgical and imaging technologies, the R&D team of CIR Biopharma has built a mature in situ and metastatic tumor models platform for evaluating the effects of drugs on the tumor itself and the tumor microenvironment of the primary lesion in which it is located. This platform provides a more valuable preclinical evaluation tool for drugs targeting tumor stromal cells, tumor angiogenesis, tumor endocrinology, tumor metabolic pathways, and tumor-regulating cytokines, especially for tumor immunotherapy, gene therapy, and cell therapy. CIR Biopharma team can perform parallel multiple imaging markers and real-time assays, capable of simultaneously evaluating tumor growth, invasion, distal metastasis and survival in model animals.

Tumor model in immunodeficient rat

The SRG rats have multiple immune deficiencies and physiological characteristics of rats, which can provide unique advantages in applications such as oncology, immunology, xenotransplantation and humanized immune system reconstitution.